← Back to guidelines
Oncology12 papers

Esophagogastric ulcer

Last edited: 4/15/2026

Overview

Esophagogastric ulcer refers to ulcers occurring in the esophagus and stomach, often associated with conditions like peptic ulcer disease, but this summary focuses on specific clinical aspects related to oligometastatic disease and anastomotic complications in esophagogastric cancer patients 1.

Diagnosis

  • Key Criteria: Identification of ≤3 metastases in one organ or involvement of one extra-regional lymph node station in esophagogastric cancer patients 1.
  • Disease-Free Interval (DFI): Defined as time from primary tumor treatment to detection of oligometastatic disease 1.
  • Imaging and Biopsy: Essential for confirming metastatic involvement; specific imaging modalities not detailed in provided abstracts 1.
  • Management

  • First-Line Treatment: Systemic therapy for oligometastatic disease, tailored based on primary tumor treatment response and metastasis characteristics 1.
  • Interventional Radiology: For esophagogastric anastomotic leakage, use of three-tube method (abscess drainage, gastrointestinal decompression, jejunal feeding) with optional temporary covered esophageal stent placement 2.
  • Supportive Care: Includes anti-inflammatory treatment, nutritional support, and monitoring for complications such as abscess resolution 2.
  • Special Populations

  • No Specific Guidance: The provided abstracts do not cover special populations including pregnancy, pediatrics, elderly, or specific comorbidities 12.
  • Key Recommendations

  • Consider oligometastatic disease (OMD) in esophagogastric cancer patients with ≤3 metastases in one organ or involvement of one extra-regional lymph node station, with ongoing consideration if no progression after systemic therapy (Evidence: Moderate) 1.
  • For esophagogastric anastomotic leakage, employ interventional radiology methods including the three-tube technique and temporary stent placement as needed, ensuring technical success and monitoring for complications (Evidence: Weak) 2.
  • Systematically manage systemic therapy based on disease-free interval and response to primary tumor treatment, adapting strategies for oligometastatic scenarios (Evidence: Moderate) 1.
  • References

    1 Kroese TE, Bronzwaer S, van Rossum PSN, Schoppman SF, Deseyne PRAJ, van Cutsem E et al.. European clinical practice guidelines for the definition, diagnosis, and treatment of oligometastatic esophagogastric cancer (OMEC-4). European journal of cancer (Oxford, England : 1990) 2024. link 2 Bi Y, Zhu X, Yu Z, Wu G, Han X, Ren J. Interventional radiology protocol for treatment of esophagogastric anastomotic leakage. La Radiologia medica 2019. link

    Original source

    1. [1]
      European clinical practice guidelines for the definition, diagnosis, and treatment of oligometastatic esophagogastric cancer (OMEC-4).Kroese TE, Bronzwaer S, van Rossum PSN, Schoppman SF, Deseyne PRAJ, van Cutsem E et al. European journal of cancer (Oxford, England : 1990) (2024)
    2. [2]
      Interventional radiology protocol for treatment of esophagogastric anastomotic leakage.Bi Y, Zhu X, Yu Z, Wu G, Han X, Ren J La Radiologia medica (2019)

    HemoChat

    by SPINAI

    Evidence-based clinical decision support powered by SNOMED-CT, Neo4j GraphRAG, and NASS/AO/NICE guidelines.

    ⚕ For clinical reference only. Not a substitute for professional judgment.

    © 2026 HemoChat. All rights reserved.
    Research·Pricing·Privacy & Terms·Refund·SNOMED-CT · NASS · AO Spine · NICE · GraphRAG